503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25
📚 Book Relaunch: The book “Decoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy.
⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25.
🔬 Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles.
💊 PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access.
📈 Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices.
🏥 Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies.
🎉 Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions
🤝 Visit Our Sponsors!
OTPLinks.com
Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen
WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv
📲 Contact Me: dave@onthepen.com
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.
More description
📚 Book Relaunch: The book “Decoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy.
⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25.
🔬 Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles.
💊 PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access.
📈 Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices.
🏥 Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies.
🎉 Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions
🤝 Visit Our Sponsors!
OTPLinks.com
Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen
WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv
📲 Contact Me: dave@onthepen.com
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.